Tezosentan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tezosentan
Tezosentan.png
Space-filling model of the tezosentan molecule
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C27H27N9O6S
Molar mass 605.624
3D model (Jmol)
  (verify)

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

References[edit]

  1. ^ Urbanowicz, W; Sogni, P; Moreau, R; Tazi, K A; Barriere, E; Poirel, O; Martin, A; Guimont, M C; Cazals-Hatem, D; Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. BMJ Publishing Group Ltd & British Society of Gastroenterology. 53 (12): 1844–1849. PMC 1774327Freely accessible. PMID 15542526. doi:10.1136/gut.2003.036517. 
  2. ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.